Phase I, Open-Label, Non-Placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2014
At a glance
- Drugs Regorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer; Bayer HealthCare
- 15 May 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003663).